JT Coyle, D Balu, M Benneyworth, A Basu… - Dialogues in clinical …, 2010 - Taylor & Francis
All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative …
AHC Wong, HHM Van Tol - Neuroscience & Biobehavioral Reviews, 2003 - Elsevier
Schizophrenia is a common and debilitating illness, characterized by chronic psychotic symptoms and psychosocial impairment that exact considerable human and economic …
LF Jarskog, S Miyamoto, JA Lieberman - Annu. Rev. Med., 2007 - annualreviews.org
The neurodevelopmental hypothesis of schizophrenia posits an interaction between multiple susceptibility genes and one or more environmental insults in early life, resulting in altered …
Schizophrenia is commonly considered a neurodevelopmental disorder that is associated with significant morbidity; however, unlike other neurodevelopmental disorders, the …
Schizophrenia is a highly disabling disorder whose causes remain to be better understood, and treatments have to be improved. However, several recent advances have been made in …
NR Swerdlow - Schizophrenia research, 2011 - Elsevier
New findings are rapidly revealing an increasingly detailed image of neural-and molecular- level dysfunction in schizophrenia, distributed throughout interconnected cortico–striato …
Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are …
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …